We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+3.66%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$201M
Cap. Flow
+$179M
Cap. Flow %
14.8%
Top 10 Hldgs %
14.79%
Holding
464
New
45
Increased
341
Reduced
52
Closed
26

Top Buys

Rank Stock Value
1
ZBRA icon
Zebra Technologies
ZBRA
+$8.61M
2
OII icon
Oceaneering
OII
+$7.8M
3
PTC icon
PTC
PTC
+$7.55M
4
CGNX icon
Cognex
CGNX
+$6.25M
5
HOLI
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
+$6.06M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.6M
2
ESLT icon
Elbit Systems
ESLT
+$4.36M
3
MBLY
Mobileye N.V.
MBLY
+$4.01M
4
BAC icon
Bank of America
BAC
+$2.75M
5
ANDV
Andeavor
ANDV
+$2.53M

Sector Composition

Rank Sector Weight
1 Technology 21.02%
2 Industrials 13.5%
3 Healthcare 11.15%
4 Financials 9.91%
5 Consumer Discretionary 7.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
276
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.48M 0.12%
49,477
+2,101
+4% +$51.8K
CATM
277
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
$1.48M 0.12%
44,876
+784
+2% +$29.4K
ATW
278
DELISTED
Atwood Oceanics
ATW
$1.47M 0.12%
180,722
+3,114
+2% +$26.8K
XHR
279
Xenia Hotels & Resorts
XHR
$1.89B
$1.47M 0.12%
75,734
+2,275
+3% +$41.5K
SNDX icon
280
Syndax Pharmaceuticals
SNDX
$1.7B
$1.45M 0.12%
+103,558
New +$1.18M
URBN icon
281
Urban Outfitters
URBN
$6.65B
$1.43M 0.12%
76,966
+1,232
+2% +$25.3K
AMZN icon
282
Amazon
AMZN
$2.99T
$1.41M 0.12%
29,080
-8,060
-22% -$385K
DVAX
283
DELISTED
Dynavax Technologies
DVAX
$1.41M 0.12%
+145,705
New +$946K
CHTR icon
284
Charter Communications
CHTR
$17.2B
$1.39M 0.11%
4,118
-601
-13% -$200K
IOSP icon
285
Innospec
IOSP
$2.11B
$1.38M 0.11%
21,083
+254
+1% +$16.3K
IBRX icon
286
ImmunityBio
IBRX
$7.49B
$1.38M 0.11%
181,152
+42,461
+31% +$183K
IOVA icon
287
Iovance Biotherapeutics
IOVA
$1.95B
$1.36M 0.11%
185,628
+60,092
+48% +$382K
AMGN icon
288
Amgen
AMGN
$204B
$1.34M 0.11%
7,756
+935
+14% +$152K
KITE
289
DELISTED
Kite Pharma, Inc.
KITE
$1.33M 0.11%
12,813
-5,147
-29% -$420K
MRK icon
290
Merck
MRK
$316B
$1.3M 0.11%
21,300
+3,796
+22% +$231K
CTMX icon
291
CytomX Therapeutics
CTMX
$690M
$1.29M 0.11%
83,392
+7,468
+10% +$113K
CLLS
292
Cellectis
CLLS
$277M
$1.29M 0.11%
49,981
-1,013
-2% -$24.2K
AGEN
293
Agenus
AGEN
$346M
$1.28M 0.11%
16,697
+6,382
+62% +$449K
ONC
294
BeOne Medicines Ltd
ONC
$32.6B
$1.28M 0.11%
28,458
-1,288
-4% -$50.8K
RDC
295
DELISTED
Rowan Companies Plc
RDC
$1.28M 0.11%
124,932
+2,130
+2% +$27.9K
TCRT icon
296
Alaunos Therapeutics
TCRT
$4.65M
$1.27M 0.11%
1,365
+445
+48% +$436K
INCY icon
297
Incyte
INCY
$24B
$1.27M 0.11%
8,568
+839
+11% +$107K
ATRA icon
298
Atara Biotherapeutics
ATRA
$77M
$1.27M 0.11%
3,624
+1,397
+63% +$538K
BLCM
299
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.24M 0.1%
10,632
+4,973
+88% +$617K
KDNY
300
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.22M 0.1%
21,411
+5,602
+35% +$281K
10 11
12
13 14

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q2 2017 Portfolio in Review

As of Q2 2017, Vident Investment Advisory held 464 positions worth $1.21B, up 20% from $1.01B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Vident Investment Advisory deployed $179M of net new capital in Q2 2017, opening 45 new positions and adding to 341 existing holdings. Its largest new stake was PTC: 137,032 shares worth $7.55M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 17% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $16.6M trimmed.

  • Vident Investment Advisory's largest Q2 2017 buy was PTC: 137,032 shares worth $7.55M.
  • Vident Investment Advisory added most to Zebra Technologies in Q2 2017, an estimated $8.61M increase.
  • Vident Investment Advisory's biggest Q2 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $16.6M.
  • Vident Investment Advisory fully exited Elbit Systems in Q2 2017, selling an estimated $4.36M.
  • Vident Investment Advisory's ten largest holdings make up 15% of its $1.21B portfolio in Q2 2017.
  • Vident Investment Advisory opened 45 new positions and closed 26 in Q2 2017.
  • Vident Investment Advisory's portfolio value rose 20% quarter-over-quarter to $1.21B.

Based on Vident Investment Advisory's 13F filing for Q2 2017, filed 11 Aug 2017.